Abbvie Inc ABBV

$265.12 +0.04 (0.02%)

Valuation

Market cap
468,341,440,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
24.40
Forward PE
18.87
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
3,458,100
Avg volume
4,788,214
Day's range
$263.09 – $267.41
Shares out
1,766,793,000
Stochastic %K
63%
Beta
0.29
Analysts
Strong Sell
Price target
$277.87

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Sep 24, 4:05 PM
$SLS $MRNA Just the Initial CR2/3 Phase 3 AML Trial Setting is worth $120 Per SLS Share - equates to $24B mcap. -• Gps Phase 3 MOS will come in > 34 months for AML patients in Second Remission (CR2) treated w Gps Immunotherapy. Gps Median Overall Survival of > 34 months is Longer than the 24.7 Month MOS for First Remission (CR1) Patients on Standard of Care -Onureg. Gps has proven effective in Preventing Relapse and extending Survival in all Prior trials - Including in 2, Phase 2 Trials for AML Remission Maintenance. • Gps P2 MOS for CR1/First Remission was Not Reached and > 67.6 months. again Standard of Care is just 24.7 months w Onureg. $ABBV combined Onureg w VENETOCLAX and Multiple Phase 3 Trials - including the VIALE-M P3 - ALL FAILS.
0 replies
DidYouReadThis Sep 24, 1:51 PM
$ABBV $NVS $REGN $OTLK If you remember the smell of the Ditto machine or know what a mimeograph is, is it about time to schedule an eye exam?
0 replies
HawkEye828 Sep 24, 12:41 PM
$PROK, may be the upcoming "Holy Grail" of Biotech. This is an Autologous treatment designed to delay or completely prevent the need for dialysis. This is one of the Govts biggest expenses. Phase 2 complete with a 78% response. Ph 3 now on board with Accelerated Approval. https://investors.prokidney.com/news-releases/news-release-details/prokidney-announces-strategic-updates-its-phase-3-program Government savings huge. National Kidney Foundation indicates Medicare spends $130 Billion--more than 24% of Total spending on kidney disease alone. $ABBV, $TMO ,$AZN , $VRTX
0 replies
Quantumup Sep 24, 11:38 AM
H.C. Wainwright reiterated $ORKA Buy-$120 $ABBV APGE $UCBJY PTGX - JNJ TAK LLY NVS Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2103086429978996837?s=20
0 replies
JCJustCharting Sep 23, 11:30 PM
$ABBV heatmap read https://x.com/jc_justcharts/status/2102902577822064895?s=46
0 replies
biolover Sep 23, 9:05 PM
$VKTX Trapped shorts always give u chance to add, imagining they will scare people 😂. At least 22 m trapped shares while $NVO $ABBV and likely $LLY and others circling. Even Lilly jets news interesting. Better to be well funded, $200M stock sale is trivial. $VKTX
0 replies
55X_ROI_Q1_2026 Sep 23, 6:48 PM
$SLS $MRNA $ABBV 12,500 CR2/3 Patients * $500K Rev per patient ​$6.25B TAM 50,000 CR1 Patients *$720K Rev Per Patient ​$36B TAM SLS Current Rigged MCAP $2.33B is about to be $25B and Climbing, the Instant the Imminent Phase 3 Results are announced.
0 replies
55X_ROI_Q1_2026 Sep 23, 6:17 PM
$SLS Gps Phase 3 MOS for Second Remission is Longer than the SOC for First Remission This $2.3B baby bio is about to grow up fast. P3 Results Imminent. • GPs CR1 - First Remission Phase 2 MOS > 67.6 Months • Onureg CR1 - First Remission MOS - 24.7 Months • Gps CR2 Second Remission Phase 2 MOS - 21 months - P2 MOS of 21 in an Older 74 yo, All MRD+ Setting - who got only 12 doses of Gps in Y1 only. We Know based on enrollment, Idmc unblinded MOS and median follow-up data + 80% IR Rates -- • Gps Phase 3 MOS will come in > 34 Months for CR2 Patients --* SOC MOS is 24.7 for CR1 $XBI $ABBV $MRNA
0 replies